The phase 1 trial was investigating a CAR-T gene therapy called P-PSMA-101, designed to treat prostate cancer.
The patient had metastatic castrate-resistant prostate cancer and died of liver failure 19 days after receiving the CAR-T treatment. He had missed two follow-up visits and developed symptoms that led to him being hospitalized, according to the SEC filing.
Poseida is waiting on a formal response from the FDA and preparing recommendations to allow the trial to resume, the drugmaker said.
The drugmaker’s shares fell 35 percent after the announcement.
More articles on pharmacy:
CVS partnering with Delta Air Lines for rapid COVID-19 testing program
Sanofi inks $3.68B deal to buy California autoimmune drugmaker
US to test benefits of remdesivir with second drug
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.